Morgan Stanley’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-36,448
| Closed | -$165K | – | 8334 |
|
|
2025
Q4 | $165K | Sell |
36,448
-171,248
| -82% | -$877K | ﹤0.01% | 6003 |
|
|
2025
Q3 | $1.12M | Buy |
207,696
+87,436
| +73% | +$473K | ﹤0.01% | 5118 |
|
|
2025
Q2 | $653K | Sell |
120,260
-13,776
| -10% | -$54.6K | ﹤0.01% | 5331 |
|
|
2025
Q1 | $371K | Buy |
134,036
+36,760
| +38% | +$128K | ﹤0.01% | 5461 |
|
|
2024
Q4 | $332K | Sell |
97,276
-48,405
| -33% | -$140K | ﹤0.01% | 5586 |
|
|
2024
Q3 | $428K | Sell |
145,681
-162,224
| -53% | -$534K | ﹤0.01% | 5472 |
|
|
2024
Q2 | $1.05M | Sell |
307,905
-536,319
| -64% | -$1.75M | ﹤0.01% | 4935 |
|
|
2024
Q1 | $2.56M | Sell |
844,224
-219,200
| -21% | -$769K | ﹤0.01% | 4414 |
|
|
2023
Q4 | $4.48M | Buy |
1,063,424
+862,122
| +428% | +$4.68M | ﹤0.01% | 4440 |
|
|
2023
Q3 | $1.37M | Sell |
201,302
-339,230
| -63% | -$3M | ﹤0.01% | 4611 |
|
|
2023
Q2 | $5.63M | Buy |
540,532
+310,280
| +135% | +$2.78M | ﹤0.01% | 3683 |
|
|
2023
Q1 | $1.6M | Sell |
230,252
-106,354
| -32% | -$927K | ﹤0.01% | 4583 |
|
|
2022
Q4 | $2.03M | Buy |
336,606
+17,311
| +5% | +$128K | ﹤0.01% | 4453 |
|
|
2022
Q3 | $2.52M | Sell |
319,295
-5,858
| -2% | -$68.3K | ﹤0.01% | 4268 |
|
|
2022
Q2 | $4.42M | Buy |
325,153
+155,996
| +92% | +$2.58M | ﹤0.01% | 3872 |
|
|
2022
Q1 | $3.32M | Buy |
169,157
+77,531
| +85% | +$1.55M | ﹤0.01% | 4104 |
|
|
2021
Q4 | $3.15M | Buy |
91,626
+23,280
| +34% | +$937K | ﹤0.01% | 4199 |
|
|
2021
Q3 | $3.73M | Buy |
68,346
+19,743
| +41% | +$1.19M | ﹤0.01% | 4026 |
|
|
2021
Q2 | $3.57M | Sell |
48,603
-4,996
| -9% | -$499K | ﹤0.01% | 4120 |
|
|
2021
Q1 | $4.9M | Buy |
53,599
+36,604
| +215% | +$3.55M | ﹤0.01% | 3430 |
|
|
2020
Q4 | $1.38M | Buy |
16,995
+7,182
| +73% | +$550K | ﹤0.01% | 4451 |
|
|
2020
Q3 | $457K | Buy |
+9,813
| New | +$547K | ﹤0.01% | 4695 |
|
Morgan Stanley's CVAC Position: Q1 2026 in Review
Morgan Stanley sold out of CureVac (CVAC) in Q1 2026, closing a stake of 36,448 shares — an estimated $165K sold.
Morgan Stanley first reported a position in CVAC in Q3 2020 and held it in 22 quarters. The position peaked at $5.63M in Q2 2023. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- Morgan Stanley reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 36,448 CureVac shares in Q1 2026, an estimated $165K.
- Morgan Stanley first reported a position in CureVac in Q3 2020 and held it in 22 quarters.
- Morgan Stanley's CureVac position peaked at $5.63M in Q2 2023.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.